T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This phase I trial is to investigate the safety and the possible side effects of bi-specific
antibody armed T-cell therapy when given together with low-dose IL-2 in treating patients
with Her2-positive neoplasms of digestive system. Expanded autologues T cells that have been
coated with bi-specific antibodies, such as anti-CD3 and anti-human epidermal growth factor
receptor 2 (HER2), may stimulate the immune system in different ways and stop tumor cells
from growing. Interleukin-2 may stimulate white blood cells to kill tumor cells.